바이오테크 보도자료
-
- Biocytogen Announces Collaboration with FineImmune to Develop TCR-Mimic Antibody-based Cell Therapy
- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announced a strategic collaboration with Guangzhou FineImmune Biotechnology Co., LTD. (“FineImmune”) to co-develop cell-based therapeutic drugs targeting intracellular tumo...
- 2022년 09월 15일
-
- Prolific Machines Raises $42M From Top Planetary Health Investors to Build the Assembly Line for Biology
- Prolific Machines, a next generation biotechnology company, is emerging from stealth today by announcing their massively oversubscribed Seed and Series A financings, led by the best VCs in the space. The Seed round was led by Arvind Gupta at Mayfi...
- 2022년 09월 15일
-
- Takeda Selects New Partners for Global Corporate Social Responsibility (CSR) Program to Strengthen Health Systems in Low- and Middle-Income Countries
- Takeda (TSE:4502/NYSE:TAK) today announced four new partnerships to its Global Corporate Social Responsibility (CSR) Program, which makes long-term commitments to strengthen healthcare for people in developing and emerging countries. Even the best...
- 2022년 09월 14일
-
- VeriSilicon Announces the One-Stop VeriHealth Chip Design Platform for Smart Healthcare Applications
- VeriSilicon (688521.SH), a leading Silicon Platform as a Service (SiPaaS®) company, today announced the launch of its customizable one-stop health chip design platform-VeriHealth™. Based on VeriSilicon’s own low-power IP series and advanced SoC cu...
- 2022년 09월 14일
-
- GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease
- GE Healthcare and Lantheus Holdings Inc (NASDAQ: LNTH) have announced that the recent Phase III clinical trial of their investigational radiotracer, [18F]flurpiridaz, has met its co-primary endpoints of exceeding a 60 percent threshold for both se...
- 2022년 09월 14일
-
- Rhizen Pharmaceuticals AG Announces Upcoming Data Presentations at ESMO 2022 for Its Clinical Stage Assets; Tenalisib in Locally Advanced/ Metastatic Breast Cancer and RP12146 in Multiple Solid Tumors
- Rhizen Pharmaceuticals AG (Rhizen), a Swiss based privately held, clinical-stage biopharmaceutical company announced today that it is presenting data from an ongoing Phase 2 trial of Tenalisib in locally advanced or metastatic breast cancer and da...
- 2022년 09월 13일
-
- PDC*line Pharma Presents First Clinical Results From Phase I/II trial With PDC*lung01 at ESMO 2022
- PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, today announces the first results of PDC-LUNG-101 phase I/II clinical trial (NCT03970746) with PDC*lung01, the comp...
- 2022년 09월 13일
-
- Xevinapant Five-Year Data Show Survival Rate Nearly Doubled in Patients with Unresected LA SCCHN, When Added to Standard of Care
- Merck, a leading science and technology company, today announced that the IAP (inhibitor of apoptosis protein) inhibitor xevinapant (formerly known as Debio 1143) plus chemoradiotherapy (CRT) markedly improved long-term efficacy outcomes in patien...
- 2022년 09월 08일
-
- Merck to Highlight Data at ESMO 2022 with Potential for Transformative Impact on Cancer Patients
- Merck, a leading science and technology company, today announced the latest research from the Company’s oncology portfolio and pipeline to be presented at this year’s European Society of Medical Oncology (ESMO) Annual Meeting, September 9-13, 2022...
- 2022년 09월 08일
-
- Kirin Holdings: Spoon and Bowl That Enhance the Salty Taste of Low-sodium Food by Approximately 1.5 Times[*1] via Stimulation.
- Kirin Holdings Company, Limited (Kirin) and the Meiji University Dr. Homei Miyashita Laboratory of the Department of Frontier Media Science, School of Interdisciplinary Mathematical Sciences (Miyashita Laboratory), have developed a unique electric...
- 2022년 09월 08일
-
- SINOVAC Approved to Initiate Clinical Trial for Its Omicron Containing COVID-19 Vaccine in Chile
- Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Chilean Public Health Institute (Instituto de Salud Pública, ISP) approved a phase II clinical trial for...
- 2022년 09월 07일
![기린 홀딩스: 자극 통해 저염 음식의 짠맛 약 1.5배[*1] 증가시키는 숟가락과 그릇 개발](http://file.newswire.co.kr/data/datafile2/thumb_big/2022/09/31017998_20220908102408_8247011677.jpg)
전시회
